|Bid||7.00 x 1000|
|Ask||7.01 x 900|
|Day's Range||6.92 - 7.15|
|52 Week Range||2.10 - 8.81|
|Beta (5Y Monthly)||2.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Those following along with Ardelyx, Inc. (NASDAQ:ARDX) will no doubt be intrigued by the recent purchase of shares by...
Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
As you might know, Ardelyx, Inc. (NASDAQ:ARDX) just kicked off its latest first-quarter results with some very strong...
MONTREAL, April 17, 2020 -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
It is doubtless a positive to see that the Ardelyx, Inc. (NASDAQ:ARDX) share price has gained some 93% in the last...
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Every investor in Ardelyx, Inc. (NASDAQ:ARDX) should be aware of the most powerful shareholder groups. Large companies...
Ardelyx (ARDX) delivered earnings and revenue surprises of -5.13% and -97.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Ardelyx, Inc. (NASDAQ:ARDX) might want to consider the historical volatility of the share price...